Novato, CA, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company’s Chief Financial Officer, will be presenting at the Wedbush PacGrow Life Sciences Management Access Conference on August 13, 2014 at 3:40pm ET in New York and at the Canaccord Genuity Growth Conference on August 14, 2014 at 10:30am ET in Boston.
The live and archived webcasts of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replays of the webcasts will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
CONTACT: Contact Ultragenyx Pharmaceutical Inc. 844-758-7273 For Media, Bee Nguyen For Investors, Robert Anstey Help employers find you! Check out all the jobs and post your resume.
